Targeting Mucosal Healing in Crohn's Disease
Michael F Picco1,2, Francis A Farraye1,2
1Dr Picco is an associate professor of medicine, consultant, chair of the Division of Gastroenterology and Hepatology, and co-director of the Inflammatory Bowel Disease Center at Mayo Clinic in Jacksonville, Florida.
Achieving mucosal healing in Crohn's disease treatment is crucial for sustained remission and preventing complications. While promising, current methods have limitations, necessitating further research into alternative assessment tools.
Area of Science:
- Gastroenterology and Hepatology
- Inflammatory Bowel Disease (IBD) Research
- Clinical Trial Endpoints
Background:
- Crohn's disease management aims to induce remission and avert long-term complications.
- Assessment of treatment efficacy has evolved from subjective symptoms to objective measures like mucosal healing.
- Mucosal healing, or endoscopic remission, is increasingly recognized as a key therapeutic outcome in Crohn's disease.
Purpose of the Study:
- To evaluate the significance of mucosal healing as a treatment goal in Crohn's disease.
- To discuss the benefits of mucosal healing, including sustained clinical remission and reduced hospitalizations.
- To identify the limitations of current mucosal healing assessment methods and explore potential alternatives.
Main Methods:
- Review of studies focusing on medical therapies for Crohn's disease with mucosal healing as an outcome.
- Analysis of data primarily from ileocolonoscopy, the standard for assessing mucosal healing.
- Consideration of emerging alternative diagnostic tools such as capsule endoscopy and noninvasive imaging.
Main Results:
- Mucosal healing is associated with higher rates of sustained clinical remission and fewer disease-related surgeries and hospitalizations.
- Ileocolonoscopy, while effective, is invasive and limited to the colon and terminal ileum.
- Alternative noninvasive methods show potential but require further validation.
Conclusions:
- Mucosal healing is a critical treatment goal for evaluating therapies in Crohn's disease clinical studies and practice.
- Despite limitations in current assessment techniques, the pursuit of mucosal healing remains vital.
- Further research is needed to refine and validate noninvasive methods for assessing mucosal healing in Crohn's disease.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:52Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...